versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.
Company profile
Ticker
ARAV
Exchange
Website
CEO
Gail McIntyre
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Versartis, Inc.
SEC CIK
Corporate docs
Subsidiaries
Aravive Biologics, Inc. ...
ARAV stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
8 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
Latest ownership filings
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Artal International S.C.A.
9 Feb 24
4
Maria Carolina Petrini
11 Apr 23
3
Maria Carolina Petrini
11 Apr 23
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 23
SC 13G/A
Artal International S.C.A.
13 Feb 23
4
Gail Frances McIntyre
2 Feb 23
4
Robert B. Geller
2 Feb 23
4
RUDY HOWARD
2 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.54 mm | 8.54 mm | 8.54 mm | 8.54 mm | 8.54 mm | 8.54 mm |
Cash burn (monthly) | 3.27 mm | 1.61 mm | 2.97 mm | 4.94 mm | 3.27 mm | 4.95 mm |
Cash used (since last report) | 21.86 mm | 10.77 mm | 19.84 mm | 32.98 mm | 21.82 mm | 33.07 mm |
Cash remaining | -13.33 mm | -2.24 mm | -11.30 mm | -24.44 mm | -13.29 mm | -24.54 mm |
Runway (months of cash) | -4.1 | -1.4 | -3.8 | -4.9 | -4.1 | -5.0 |
Institutional ownership, Q3 2023
83.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 39 |
Opened positions | 13 |
Closed positions | 18 |
Increased positions | 7 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 557.90 mm |
Total shares | 61.66 mm |
Total puts | 13.10 k |
Total calls | 7.41 k |
Total put/call ratio | 1.8 |
Largest owners | Shares | Value |
---|---|---|
Eshelman Ventures | 26.38 mm | $20.97 mm |
Artal International S.C.A. | 12.18 mm | $0.00 |
Eshelman Fredric N | 10.07 mm | $18.94 mm |
Biotechnology Value Fund L P | 6.11 mm | $6.42 mm |
Acadian Asset Management | 2.01 mm | $263.00 k |
Vanguard | 1.14 mm | $150.41 mm |
New Leaf Biopharma Opportunities II | 946.42 k | $2.07 mm |
Millennium Management | 395.80 k | $52.25 mm |
Affinity Asset Advisors | 346.51 k | $45.74 mm |
BLK Blackrock | 317.72 k | $41.94 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Apr 23 | Maria Carolina Petrini | Nonqualified Stock Option Common Stock | Grant | Acquire A | No | No | 1.86 | 400,000 | 744.00 k | 400,000 |
1 Feb 23 | Leonard Scott Dove | Stock Option Common Stock | Grant | Acquire A | No | No | 1.67 | 400,000 | 668.00 k | 400,000 |
1 Feb 23 | Rudy Howard | Stock Option Common Stock | Grant | Acquire A | No | No | 1.67 | 400,000 | 668.00 k | 400,000 |
1 Feb 23 | McIntyre Gail Frances | Stock Option Common Stock | Grant | Acquire A | No | No | 1.67 | 700,000 | 1.17 mm | 700,000 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
26 Jan 24
Why 3M Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
23 Jan 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
23 Jan 24
Why United Airlines Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
23 Jan 24